Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 17, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, disclosure
TL;DR
Haleon bought back some of its own stock on Sept 17. Details light.
AI Summary
Haleon plc announced on September 17, 2024, that it has completed a transaction involving its own shares. The filing, a Form 6-K, details this transaction as part of its reporting requirements for foreign private issuers. No specific financial figures or share counts were disclosed in this particular filing.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which can be a signal to investors about management's view of the company's valuation or capital allocation strategies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a share transaction and does not contain information that inherently increases risk.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former company name
- September 17, 2024 (date) — Date of transaction and filing
FAQ
What type of transaction did Haleon plc conduct in its own shares?
Haleon plc conducted a transaction in its own shares, as detailed in Exhibit 99.1 of the Form 6-K filed on September 17, 2024.
What is the filing type and date?
The filing is a Form 6-K, reported for the month of September 2024, and filed as of September 17, 2024.
What was Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd, with a date of name change on December 17, 2021.
Where is Haleon plc's principal executive office located?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Does Haleon plc file annual reports under Form 20-F or 40-F?
Haleon plc indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-17 12:41:48
Filing Documents
- a5765e.htm (6-K) — 29KB
- 0001654954-24-012011.txt ( ) — 31KB
From the Filing
IN OWN SHARES a5765e   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  17 September 2024 - “Transaction in Own Shares”         99.1           Haleon plc: Transaction in own shares   17 September 2024: Haleon plc (the “Company” or “Haleon”) today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the “Shares”) for cancellation under its share buyback programme announced on 1 August 2024 (the “Buyback Programme”).   Date of purchase: 17 September 2024 Number of Shares purchased: 645,140 Highest price paid per Share (p): 397.9000 Lowest price paid per Share (p): 394.8000 Volume weighted average price paid per Share (p): 396.4085   Following the settlement of the above, the Company's registered share capital consists of 9,117,826,432 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/5763E_1-2024-9-17.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors .   Enquiries     Investors Media Sonya Ghobrial +44 7392 784784 Zoë Bird +44 7736 746167 Rakesh Patel +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email: investor-relations@haleon.com Email: corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .                        SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 17, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary